ReviewDrugs2010
Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis.American journal of Alzheimer's disease and other dementias · 2019Pooled it
- Feasibility of identifying factors related to Alzheimer's disease and related dementia in real-world data.JAMIA open · 2026Review
- Review
- Gut microbiota and circadian rhythm in Alzheimer's disease pathophysiology: a review and hypothesis on their association.npj aging · 2023Review
- Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.Clinical and experimental immunology · 2022Article
- IgG Epitopes Processed and Presented by IgGJournal of immunology (Baltimore, Md. : 1950) · 2021Observational
- Linalool Alleviates AOxidative medicine and cellular longevity · 2021Article
- Advances in Drug Therapy for Alzheimer's Disease.Current medical science · 2020Review
- The effects of human leukocyte antigen DRB1*13 and apolipoprotein E on age-related variability of synchronous neural interactions in healthy women.EBioMedicine · 2018Article
- Anti-α4β1 Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer's Disease.Current Alzheimer research · 2018Article
- The Government's role in regulating, coordinating, and standardizing the response to Alzheimer's disease: Anticipated international cooperation in the area of intractable and rare diseases.Intractable & rare diseases research · 2016Review
- IgG Conformer's Binding to Amyloidogenic Aggregates.PloS one · 2015Article
- Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Journal of neuroinflammation · 2014Review
- Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.Journal of neuroimmunology · 2014Article
- Immunomodulation and AD--down but not out.Journal of clinical immunology · 2014Review
- Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target.Journal of clinical immunology · 2014Review
- Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease.Journal of clinical immunology · 2014Article
- The role of choroid plexus in IVIG-induced beta-amyloid clearance.Neuroscience · 2014Article
- IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology.Journal of neuroinflammation · 2014Article
- Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.Journal of internal medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current treatment options for Alzheimer's disease (AD) exert only a short-lived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing beta-amyloid (Abeta) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Abeta) that specifically recognize and block the toxic effects of Abeta. Furthermore, these nAbs-Abeta are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Abeta, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.